While the coronavirus outbreak grows worldwide, at SOM Biotech we continue working on our pipeline to bring therapies for patients with rare diseases. It is now more important than ever to advance with the support of patients with chronic rare conditions. The development of the SOM3355 program for Chorea in Huntington’s disease in Phase 2 is bringing good results. The candidates, SOM0208 for Niemann Pick C and SOM1311 for PKU advance into in vivo stage after positive hits confirmations in vitro, which, once again, show the high efficacy of our SOMAI PRO technology.
Moreover, we continue working on 20 additional rare disease programs, that are at early stages right now but gradually progressing to become a relevant contribution to our main pipeline.
Here we are, on the call with our team. Wishing everyone to stay safe and healthy!
El equipo de investigadores observó cambios en el...
El gen AtCDF3 promueve una mayor producción de az...
Un estudio con datos de los últimos 35 años, ind...
En nuestro post hablamos sobre este interesante tipo de célula del si...
La revista ‘Nature Protocols’ selecciona esta técnica como “pro...
